Stock Markets June 30, 2026 05:54 PM

iHerb Taps JPMorgan, Morgan Stanley and Citigroup for Targeted $500M IPO

Irvine-based vitamin and supplement e-retailer lines up lead banks as it eyes a possible public listing this year

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
JPM MS C KR

iHerb, an online retailer of vitamins, supplements and health-and-wellness products, has selected JPMorgan Chase, Morgan Stanley and Citigroup to lead an initial public offering that could raise roughly $500 million. The Irvine, California company, which reported more than $2.8 billion in sales last year and said it was profitable, completed an acquisition of Kroger's Vitacost earlier this year and has previously filed confidential IPO paperwork.

iHerb Taps JPMorgan, Morgan Stanley and Citigroup for Targeted $500M IPO
JPM MS C KR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • iHerb has appointed JPMorgan Chase, Morgan Stanley and Citigroup as lead banks for a proposed IPO targeting roughly $500 million.
  • The Irvine-based online retailer recorded more than $2.8 billion in sales last year and said it was profitable; it serves over 15 million customers in 180+ countries and employs over 3,000 people.
  • Sectors impacted include consumer e-commerce and health-and-wellness retail, while capital markets activity will involve investment banking teams at the selected banks.

iHerb has chosen a trio of major banks to lead a planned initial public offering, according to people familiar with the matter. The health and wellness e-commerce company picked JPMorgan Chase & Co., Morgan Stanley and Citigroup Inc. to serve as lead underwriters for an offering that is expected to target about $500 million in proceeds.

The company is headquartered in Irvine, California, and officials have signaled that a listing could take place as soon as this year. Insiders cautioned that deliberations remain active and that the structure or timing of the proposed IPO could change.

Business footprint and scale

iHerb operates an online retail platform specializing in vitamins and supplements, while also offering sports nutrition, beauty, bath and personal care, grocery, baby and pet care items. The retailer sources products from nearly 2,000 brands and reports a global workforce of more than 3,000 employees. The company serves over 15 million customers across more than 180 countries.

Earlier this year, iHerb closed its acquisition of Vitacost from Kroger Co. as part of an effort to broaden its presence in the U.S. market.

Financial snapshot and prior IPO activity

According to comments from the company's finance chief, Mike Cody, iHerb generated in excess of $2.8 billion in sales last year and was profitable. The company previously submitted confidential IPO paperwork in 2021 but later abandoned those plans in early 2022.

What is known and what remains uncertain

Public reporting indicates the selection of JPMorgan, Morgan Stanley and Citigroup as lead banks and cites the roughly $500 million fundraising target. Beyond those items, sources indicate discussions are ongoing and details could be adjusted prior to any final filing or pricing decision. A potential listing timeframe - described by one source as possibly "as soon as this year" - remains contingent on internal deliberations and market conditions.

Given the business lines described, the principal operational focus cited is direct-to-consumer retailing across health, wellness and personal care categories, with an expanding U.S. footprint following the Vitacost acquisition.


Source limitations

This report presents the available, attributable details about planned underwriting appointments, the targeted fundraising amount, company size metrics, recent acquisition activity, last years revenues and prior confidential IPO filing history. Observers noted that additional specifics have not been finalized and could change.

Risks

  • Timing and deal structure are unsettled - deliberations are ongoing and details of the proposed IPO could change, which creates execution risk for the offering.
  • The company previously filed confidential IPO paperwork in 2021 then abandoned those plans in early 2022, indicating historical uncertainty around pursuing a public listing.
  • Market and strategic risks tied to integration and U.S. expansion following the acquisition of Krogers Vitacost remain, given that the acquisition was completed only earlier this year.

More from Stock Markets

South32 to divest most aluminium holdings to Alcoa in deal valued up to $5.6 billion Jun 30, 2026 Mizuho Amplifies TSMC CoWoS Capacity Outlook as Server CPU Demand Accelerates Jun 30, 2026 Health Canada Clears Apotex’s SEVMIA™ as Canada’s First Generic Wegovy® Equivalent Jun 30, 2026 Nutrabolt Selects Lead Banks as It Prepares for Potential U.S. IPO of up to $1 Billion Jun 30, 2026 Nutrabolt Lines Up Banks for Potential $1 Billion IPO Jun 30, 2026